Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

Anti-Diabetic API Products

Get access to Dr. Reddys largest Anti-diabetic API portfolios to support your formulation success.

Dr. Reddy's offers a wide selection of anti-diabetic active pharmaceutical ingredients used in the production of formulations to treat a wide range of metabolic diseases. Catering to the needs of anti-diabetic formulators, we have been manufacturing and supplying anti-diabetic APIs for over two decades.

Meeting the needs of formulation manufacturers, Dr. Reddy's provides customized particle size distribution for Anti-diabetic APIs. We are a reliable API partner with a de-risked supply chain model and complete backward integration, ensuring timely supplies to meet your demand.

Dr. Reddy's has been recognized as one of the largest, reliable manufacturers of Anti-diabetic APIs. With a production capability of multi-tonnes per year, our APIs are part of medicines across the globe, formulated by partners around the world.

We offer a broad portfolio of APIs catering to Anti- Diabetic therapy, understanding the global demand, and supporting our customers with their launch requirements. Some of the critical classes of APIs under our Anti-diabetic portfolio include:

Our team of process and analytical experts draw on their integrated understanding of IP, regulatory affairs, process development (API & formulation), and API manufacturing to ensure early entry into the market. This is of particular importance to select the optimal synthesis route in the context of the IP situation.

Other aspects are the solid-state forms and particle characteristics that are critical in formulation development. Therefore, extensive analytical tools and techniques such as 1H NMR, 13 C NMR, 2 D NMR, HRMS, DSC, TGA, IR, SEM, and PXRD have been used to elucidate the API structure, compare the different solid forms, and demonstrate the chemical and physical attributes of the API.

It is ensured that the APIs are free from potential genotoxic and carcinogenic impurities, and a control strategy has been defined by using the QbD approach at every step of the synthesis.

We stay committed to ensuring that we continue to provide high-quality and safe APIs to our partners

We offer:

  • End to end solutions
  • Best in class quality
  • cGMP manufacturing capacities
  • Continuous process innovation
  • Back-ward integration
  • Consistent supply on a commercial scale.
  • Regulatory and early launch advantage
Explore Anti-Diabetic Products

Canagliflozin Hemihydrate

Therapy Area

Dapagliflozin (Amorphous)

Therapy Area

Dapagliflozin (PG Solvate Monohydrate)

Therapy Area

Doxazosin Mesylate

Therapy Area


Therapy Area


Therapy Area


Therapy Area

Pioglitazone Hydrochloride

Therapy Area


Therapy Area


Therapy Area

Sitagliptin Hydrochloride

Therapy Area

Sitagliptin Phosphate (Monohydrate & Anhydrous)

Therapy Area


Therapy Area


Dr. Reddy’s is well-positioned to meet the global demand for Anti-Diabetic APIs. As for many of our APIs, the key starting materials (KSM) are backward integrated today. We’ve also established strategic solid sourcing and logistics partnerships and work closely with our customers to successfully manage the capacities of our manufacturing units ahead of launches.

To know more about our end-to-end solutions for Anti-diabetic formulations and Dosage forms. Check out our board portfolio of Anti-Diabetic APIs here (or) Contact us at

Explore other Therapeutic categories.


The major Anti-diabetic APIs are classified as:

  • Sodium-glucose co-transporter 2 (SGLT2) inhibitors
  • Glucagon-like peptide-1
  • Sulfonylureas
  • Thiazolidinediones

Antidiabetic APIs act by:

  • Direct stimulation of the GLP-1
  • Increase insulin secretion from pancreatic β-cells
  • Reduce glucagon release
  • Gluconeogenesis and causes a decrease in insulin resistance
  • Reduce intestinal glucose absorption
  • Increased glucosuria through the inhibition of SGLT-2 in the kidney

The Antidiabetics Market size was USD 85.5 billion in 2022 and will grow at a CAGR of 10.7% from 2022 to 2026.

In May 2022, the FDA approved Mounjaro (also known as tirzepatide) for type 2 diabetes management and diet and exercise. This first-in-class medication has been shown to improve glucose levels and weight dramatically in clinical trials.


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.

Checked out our

API Linkedin
page yet?

Follow this page to explore how our offerings can accelerate your formulation success

Click here to visit